Keith Bellovich is a Nephrology physician affiliated with Detroit R&D. OpenAlex indexes 39 publications with 2,466 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
18001 E 10 Mile Rd
Suite 1
Roseville, MI 480663803
Telephone
586-218-5800Registry record last updated 17 Feb 2016.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- AKEBIA THERAPEUTICS INCProgram year20241 payment
- Vifor Pharma, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
59.7%Aldosterone antagonist (MRA)17.1%Spironolactone100%Part D≥11 patientsAngiotensin receptor blocker (ARB)14.8%Losartan Potassium100%Part D≥14 patients+ 4 more classes in this area
Metabolism & gastrointestinal
22.8%SGLT2 inhibitor11.8%Farxiga100%Part D<11 patientsCorticosteroid6.1%Prednisone100%Part D<11 patients+ 1 more class in this area
Musculoskeletal
12.9%Xanthine oxidase inhibitor12.9%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD
Journal of the American Society of Nephrology
2025 - Improving Vaccination in People With CKD: Report From a National Kidney Foundation Working Group
American Journal of Kidney Diseases
2025 - Adrenal Tumor Masquerading as Electrolyte Imbalance: A Case Report
Journal of the American Society of Nephrology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”